Drugs with known pharmacological profiles, such as monensin, disulfiram and salinomycin, show cancer-selective inhibition of prostate cancer cell growth by increasing oxidative stress

Kirsi Ketola; Paula Vainio; Pasi Halonen; Pekka Kohonen; Vidal Fey; Roland Grafström; Merja Perälä; Olli Kallioniemi; Kristiina Iljin

doi:10.1016/S1359-6349(10)71041-7

Drugs with known pharmacological profiles, such as monensin, disulfiram and salinomycin, show cancer-selective inhibition of prostate cancer cell growth by increasing oxidative stress

Kirsi Ketola, Paula Vainio, Pasi Halonen, Pekka Kohonen, Vidal Fey, Roland Grafström, Merja Perälä, Olli Kallioniemi, Kristiina Iljin

Research output: Contribution to journal › Other journal contribution › Scientific › peer-review

Original language	English
Article number	234
Pages (from-to)	61-62
Journal	European Journal of Cancer: Supplement
Volume	8
Issue number	5
DOIs	https://doi.org/10.1016/S1359-6349(10)71041-7
Publication status	Published - 2010
MoE publication type	Not Eligible
Event	21st Meeting of the European Association for Cancer Research, EACR-21 - Oslo, Norway Duration: 26 Jun 2010 → 29 Jun 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S1359-6349(10)71041-7

Cite this

Ketola, K., Vainio, P., Halonen, P., Kohonen, P., Fey, V., Grafström, R., Perälä, M., Kallioniemi, O., & Iljin, K. (2010). Drugs with known pharmacological profiles, such as monensin, disulfiram and salinomycin, show cancer-selective inhibition of prostate cancer cell growth by increasing oxidative stress. European Journal of Cancer: Supplement, 8(5), 61-62. Article 234. https://doi.org/10.1016/S1359-6349(10)71041-7

@article{bf5119b108fd4b40895684e2ae29e928,

title = "Drugs with known pharmacological profiles, such as monensin, disulfiram and salinomycin, show cancer-selective inhibition of prostate cancer cell growth by increasing oxidative stress",

author = "Kirsi Ketola and Paula Vainio and Pasi Halonen and Pekka Kohonen and Vidal Fey and Roland Grafstr{\"o}m and Merja Per{\"a}l{\"a} and Olli Kallioniemi and Kristiina Iljin",

note = "Poster abstract; 21st Meeting of the European Association for Cancer Research, EACR-21, EACR-21 ; Conference date: 26-06-2010 Through 29-06-2010",

year = "2010",

doi = "10.1016/S1359-6349(10)71041-7",

language = "English",

volume = "8",

pages = "61--62",

journal = "European Journal of Cancer: Supplement",

issn = "1359-6349",

publisher = "Elsevier Ltd.",

number = "5",

}

Ketola, K, Vainio, P, Halonen, P, Kohonen, P, Fey, V, Grafström, R, Perälä, M, Kallioniemi, O & Iljin, K 2010, 'Drugs with known pharmacological profiles, such as monensin, disulfiram and salinomycin, show cancer-selective inhibition of prostate cancer cell growth by increasing oxidative stress', European Journal of Cancer: Supplement, vol. 8, no. 5, 234, pp. 61-62. https://doi.org/10.1016/S1359-6349(10)71041-7

Drugs with known pharmacological profiles, such as monensin, disulfiram and salinomycin, show cancer-selective inhibition of prostate cancer cell growth by increasing oxidative stress. / Ketola, Kirsi; Vainio, Paula; Halonen, Pasi et al.
In: European Journal of Cancer: Supplement, Vol. 8, No. 5, 234, 2010, p. 61-62.

Research output: Contribution to journal › Other journal contribution › Scientific › peer-review

TY - JOUR

T1 - Drugs with known pharmacological profiles, such as monensin, disulfiram and salinomycin, show cancer-selective inhibition of prostate cancer cell growth by increasing oxidative stress

AU - Ketola, Kirsi

AU - Vainio, Paula

AU - Halonen, Pasi

AU - Kohonen, Pekka

AU - Fey, Vidal

AU - Grafström, Roland

AU - Perälä, Merja

AU - Kallioniemi, Olli

AU - Iljin, Kristiina

N1 - Poster abstract

PY - 2010

Y1 - 2010

U2 - 10.1016/S1359-6349(10)71041-7

DO - 10.1016/S1359-6349(10)71041-7

M3 - Other journal contribution

SN - 1359-6349

VL - 8

SP - 61

EP - 62

JO - European Journal of Cancer: Supplement

JF - European Journal of Cancer: Supplement

IS - 5

M1 - 234

T2 - 21st Meeting of the European Association for Cancer Research, EACR-21

Y2 - 26 June 2010 through 29 June 2010

ER -